breast cancer

[Oncoimmunology] Researchers investigated the effects of CDK4/6i, abemaciclib and palbociclib, on the immunopeptidome at nontoxic levels in breast cancer cell lines using biochemical identification of HLA ligands followed by network analyses.

[npj Breast Cancer] To determine how TNBC suppresses antitumor macrophages, scientists used microRNA-200c, a powerful repressor of epithelial-to-mesenchymal transition, to drive mesenchymal-like mouse mammary carcinoma and human TNBC cells toward a more epithelial state.

[npj Breast Cancer] Researchers established the efficacy of combining neratinib (N) with trastuzumab (T) and support clinical testing to investigate the efficacy of N + T with or without chemotherapy in the neoadjuvant setting for HER2+ breast cancer.

[Cell Death & Disease] Scientists investigated the expression and function of SEC61G in breast cancer, and demonstrated that knockdown of SEC61G suppressed breast cancer cell proliferation, migration, invasion, and promoted breast cancer cell apoptosis in vitro.

[Cancer Gene Therapy] The authors found miR-328-3p to be significantly downregulated in breast cancer, revealing it as a potential therapeutic target for the treatment of breast cancer patients with metastasis, and also as a model for the miRNA-fatty acid β-oxidation-stemness axis.

[Scientific Reports] Scientists screened previously established S. aureus ClpXP inhibitors against the related human protease complex and identified potent small molecules against human ClpXP. The hit compounds showed anti-cancer activity in a panoply of leukemia, liver and breast cancer cell lines.